Stock of the Day

October 14, 2022

Rocket Pharmaceuticals (RCKT)

$3.72
-$0.14 (-3.6%)
Market Cap: $423.73M

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Today's Trend

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has been pressured by a mix of weaker analyst earnings expectations and insider selling, even as some Wall Street firms remain constructive on the stock. The shares have been moving lower recently, with investors focusing on the company’s Q1 earnings miss and the uncertain ramp of its newly approved gene therapy, Kresladi.

  • Chardan Capital reaffirmed its Buy rating on Rocket Pharmaceuticals and maintained an $11.00 price target, suggesting meaningful upside from current levels. Article Title
  • Lifesci Capital still has a Strong-Buy rating on Rocket Pharmaceuticals, even after adjusting some quarterly estimates, indicating continued analyst support for the name.
  • Lifesci Capital raised its Q2 2026 EPS estimate for Rocket Pharmaceuticals to $1.02 from a prior loss estimate, partially offsetting weaker expectations for later quarters.
  • Insider Sarbani Chaudhuri sold 17,650 shares, but the company said the sale was made to cover tax withholding obligations tied to equity vesting, which reduces the signal for investors. Article Title
  • Lifesci Capital lowered its Q3 2026 and Q4 2026 EPS estimates for Rocket Pharmaceuticals, reinforcing concerns that profitability may remain under pressure.
  • The company’s Q1 earnings miss and the market’s focus on the commercial launch of Kresladi have weighed on sentiment, as investors wait for proof of execution. Article Title

Overall, Rocket Pharmaceuticals (NASDAQ: RCKT) is being pulled in opposite directions: bullish analyst ratings and a high price target support the stock, but reduced earnings estimates, a recent earnings miss, and insider selling are keeping sentiment cautious.

← Previous Stock of the DayNext Stock of the Day →